BO
BioInvent International AB (publ)
BOVNF · OTC
$6.63 +101.61% (+$3.34)
Market Cap 2.13B kr
P/E Ratio -
Div. Yield -
ROE 99.64%
Bulios Fair Price
$5.89
11.2% downside
Current Price
$6.63
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BOVNF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
8 /100
Expensive P/B 6.76x
P/S 65.67x
EV/FFO N/A
Growth
0 /100
Declining Book val. growth 29.78%
Rev. growth 11.52%
FCF growth N/A
Profitability
20 /100
Weak Net margin 1,530.01%
Op. margin 1,568.54%
FCF margin 1,364.46%
Quality
1 /100
Poor ROE 99.64%
ROA 117.84%
Asset turnover 0.08x
Debt
100 /100
Low Current ratio 4.06x
Debt/Equity 0.07x
Net debt/EBITDA N/A
Stability
1 /100
Unstable Rev. volatility 268.29%
EPS volatility 467.73%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BOVNF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Martin Welschof
Employees
109
Headquarters
Lund
Upcoming events
29 OCT
Earnings
Upcoming earnings report